Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Celsion Corp. (NASDAQ: CLSN).

Full DD Report for CLSN

You must become a subscriber to view this report.


Recent News from (NASDAQ: CLSN)

Report: Exploring Fundamental Drivers Behind The ExOne, Switch, Monotype Imaging, Celsion, TrueCar, and Sandstorm Gold - New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Oct. 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of The ExOne Company (NASDAQ:XONE), Switch, Inc. (NYSE:SWCH), Monotype Im...
Source: GlobeNewswire
Date: October, 25 2018 08:40
Celsion Announces First Patient Randomized in the Gene-Mediated Immunotherapy (GEN-1) Study of Newly Diagnosed Stage III/IV Ovarian Cancer Patients
OVATION II Study Will Evaluate Initial and Maintenance Dosing of GEN-1 on Progression-Free Survival in a Two-Arm, Randomized Trial of Up to 130 Patients LAWRENCEVILLE, N.J., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development compan...
Source: GlobeNewswire
Date: September, 06 2018 08:00
Celsion Announces Enrollment Completion for Pivotal Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
  550 Patient Study Designed to Determine if ThermoDox® Can Significantly Prolong the Lives of Patients with Liver Cancer OPTIMA Study’s Hypothesis Independently Confirmed by the National Institutes of Health LAWRENCEVILLE, NJ, Sept. 05, 2018 (GLOBE NEWSWIRE) -- ...
Source: GlobeNewswire
Date: September, 05 2018 08:00
Factors of Influence in 2018, Key Indicators and Opportunity within Aerie Pharmaceuticals, BioScrip, Celsion, Primoris Services, Cyclacel Pharmaceuticals, and Barnes Group - New Research Emphasizes Economic Growth
NEW YORK, Sept. 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), BioScrip, Inc. (NASDAQ:BIOS),...
Source: GlobeNewswire
Date: September, 05 2018 07:30
Celsion Strengthens Its Balance Sheet with the Approval of Its Application to Sell Net Operating Losses for up to $10 Million in Non-Dilutive Funding
  Funding Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program LAWRENCEVILLE, N.J., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced it has received approval from the New Jer...
Source: GlobeNewswire
Date: September, 04 2018 08:30
Factors of Influence in 2018, Key Indicators and Opportunity within Celsion, Alpha and Omega Semiconductor, SP Plus, Merrimack Pharmaceuticals, La Jolla Pharmaceutical, and SPX - New Research Emphasizes Economic Growth
NEW YORK, Aug. 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Celsion Corporation (NASDAQ:CLSN), Alpha and Omega Semiconductor Limited ...
Source: GlobeNewswire
Date: August, 16 2018 08:00
Celsion Corporation (CLSN) CEO Mike Tardugno on Q2 2018 Results - Earnings Call Transcript
Celsion Corporation (CLSN) Q2 2018 Earnings Conference Call August 14, 2018 11:00 AM ET Executives Jeff Church - Senior Vice President and Chief Financial Officer Mike Tardugno - President and CEO Nicolas Borys - Chief Medical Officer Analysts Edward Sherman - DSW Associate...
Source: SeekingAlpha
Date: August, 14 2018 14:59
Celsion net loss widens in Q2
Celsion ( CLSN ) Q2 results : Revenues: $0.1M (unch); Net Loss: ($8.2M) (-67.3%); Loss Per Share: ($0.46) (+41.8%); Quick Assets: $12.8M (+12.3%). More news on: Celsion Corporation, Healthcare stocks news, Earnings news and commentary, , Read more ...
Source: SeekingAlpha
Date: August, 14 2018 08:54
Celsion Corporation Reports Second Quarter 2018 Financial Results and Provides Business Update
  Strong Balance Sheet With Cash Sufficient to Fund Operations Into the First Half of 2020 Quarterly and Year-to-Date Cash Expenses Consistent With Prior Guidance                Company to Hold Conference Call on ...
Source: GlobeNewswire
Date: August, 14 2018 08:30
Celsion Corporation to Hold Second Quarter 2018 Financial Results Conference Call on Tuesday, August 14, 2018
LAWRENCEVILLE, N.J, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended June 30, 2018 and provide an update on its development programs for ThermoDox®, its p...
Source: GlobeNewswire
Date: August, 07 2018 09:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-121.951.95011.991.9434,625
2018-12-112.011.93652.121.9260,235
2018-12-102.002.012.142.0074,737
2018-12-071.902.102.151.8944164,195
2018-12-061.931.962.0051.929651,176

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-122,73813,77419.8780Cover
2018-12-1181529,9132.7246Cover
2018-12-1080025,0133.1983Cover
2018-12-0710,09551,79119.4918Cover
2018-12-064,4348,54251.9082Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CLSN.


About Celsion Corp. (NASDAQ: CLSN)

Logo for Celsion Corp. (NASDAQ: CLSN)

Not available

 

Contact Information

 

 

Current Management

  • Anthony P. Deasey / CFO, COO

Current Share Structure

  • Market Cap: $46,301,491 - 05/15/2018
  • Issue and Outstanding: 17,740,035 - 03/26/2018

 


Recent Filings from (NASDAQ: CLSN)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 11 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 11 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 27 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 27 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: February, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 06 2018

 

 


Daily Technical Chart for (NASDAQ: CLSN)

Daily Technical Chart for (NASDAQ: CLSN)


Stay tuned for daily updates and more on (NASDAQ: CLSN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CLSN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CLSN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CLSN and does not buy, sell, or trade any shares of CLSN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/